EMA Authorised: Tysabri (natalizumab) — Biogen Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised the marketing of Tysabri (natalizumab) by Biogen Netherlands B.V. for the treatment of Multiple Sclerosis (decision dat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Biogen Netherlands B.V.. Decision date: 09/01/2026